These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38574721)

  • 1. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
    Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
    Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
    Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Patient Prefer Adherence; 2020; 14():2187-2199. PubMed ID: 33177813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
    Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton DJ; Chen H; Johnson ML; Aparasu RR
    Pharmacotherapy; 2021 May; 41(5):440-450. PubMed ID: 33641232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
    Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
    Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
    Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
    Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
    J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral agents in multiple sclerosis.
    Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
    Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.